Coronavirus company news summary - UK launches trial on optimal vaccine dose spacing for pregnant women - Vinbiocare to produce Arcturus's experimental mRNA Covid-19 vaccine in Vietnam
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – UK launches trial on optimal vaccine dose spacing for pregnant women – Vinbiocare to produce Arcturus’s experimental mRNA Covid-19 vaccine in Vietnam

03 Aug 2021

A new clinical trial funded by the UK Government has been launched to determine the optimal interval between Covid-19 vaccine doses for pregnant women. The Preg-CoV trial will gather immune response data on the Pfizer-BioNTech and Moderna Covid-19 vaccines given at four to six weeks or eight to 12 weeks dose intervals in a total of 600 pregnant women.

Arcturus Therapeutics has partnered with Vinbiocare Biotechnology to set up a manufacturing plant in Vietnam to produce its experimental mRNA Covid-19 vaccines for potential use in the country. Vinbiocare will get an exclusive licence to produce Arcturus’s Covid-19 vaccines at the new facility for supply only in Vietnam. Vinbiocare has secured approval from the Vietnam Ministry of Health to trial Arcturus’s vaccine, ARCT-154, against SARS-CoV-2 variants of concern.

India-based Glenmark Pharmaceuticals has entered an exclusive long-term strategic collaboration with Canadian company SaNOtize Research & Development to produce, commercialise and supply its nitric oxide nasal spray to treat Covid-19. The deal covers Asian markets, including India, Singapore, Hong Kong and Malaysia. The antimicrobial treatment is intended to kill the virus in the upper airways, thereby stopping its incubation and spread to the lungs.